Stig Linder
A new study conducted by scientists from the Dana-Farber Cancer Institute at Harvard Medical School and Karolinska Institutet presents very promising results for the treatment of the cancer form multiple myeloma.
The drug candidate used in the research has been developed by scientists from Karolinska Institutet and a Swedish company following its initial identification at the same university. The findings are so promising that the scientists are teaming up with Harvard to bring the drug to clinical trials on patients.
The journal Blood has published a new study on a drug candidate for multiple myeloma, a form of cancer that affects about one per cent of all tumour patients, with some 600 people a year developing the disease in Sweden. Multiple myeloma is a life-threatening disease and there is a dire medical need for new therapies, especially for the patients whose tumour cells have become resistant to the conventional drugs.
“The discovery that our substance works on multiple myeloma cells resistant to conventional therapy is very promising for the future, says Professor Stig Linder at Karolinska Institutet’s Department of Oncology-Pathology. “We’re now very hopeful that we and our colleagues at Harvard Medical School will be able to develop an effective treatment.”
The study demonstrates that the drug candidate, called VLX1570, inhibits tumour growth and prolongs survival in preclinical multiple myeloma models. The exact mechanism of action of the substance was identified earlier at Karolinska Institutet (Nature Medicine, 2011). Put simply, the tumour cells can be said to be more sensitive than normal cells to disruption to the machinery that breaks down defective proteins. When this machinery is blocked, it triggers apoptosis (programmed cell death) in the tumour cells.
“We show that the drug candidate kills multiple myeloma cells from cancer patients,” says Professor Linder. “The substance is also effective against myeloma cells that have developed a resistance to the clinically used drug bortezomib.”
Dr Dharminder Chauhan at Harvard Medical School says that the mechanism of action is very interesting as regards the development of new cancer drugs and adds, “We’re delighted to be able to study the therapeutic potential of this new drug candidate in clinical studies. We hope that the joint research we’re doing will lead to improved cancer treatments.”
The study also found that the new substance could be combined synergistically with other cancer therapies. Karolinska Institutet and Harvard Medical School are due to launch a large-scale clinical study next year in association with drug discovery company Vivolux AB (Uppsala, Sweden).
“If the study proves successful it will represent a great step forward, mainly for all cancer patients but also for the Swedish drug industry,” says Professor Linder.
The Latest on: Cancer therapies
- Thriving Pink offers virtual breast-cancer workshopson February 27, 2021 at 7:12 pm
Thriving Pink is offering two virtual workshop presentations for those diagnosed with breast cancer. At 7 p.m.
- State-of-the-art Skin Cancer Treatment In Bayon February 27, 2021 at 5:38 pm
The launch of a new dermatology practice offering the ‘gold standard’ in skin cancer treatment was celebrated with nibbles and mocktails on Wednesday [February 24]. Specialist dermatologist and ...
- Study on artificial microswimmers could improve the efficacy of targeted cancer therapyon February 27, 2021 at 12:15 am
A Mason Engineering researcher has discovered that artificial microswimmers accumulate where their speed is minimized, an idea that could have implications for improving the efficacy of targeted ...
- My prostate cancer journey: Testosterone reduction, mini-radiation treatments, embedded radioactive seeds and lots of difficult side effectson February 26, 2021 at 3:49 pm
The year-long treatment’s effects made many things harder. And those seeds mean I might set off radiation detectors at borders and I can’t let my grandkids sit on my lap.
- Cancer Survivors Concerned About Treatment, Health Care Disruptions During COVID-19 Pandemicon February 26, 2021 at 10:30 am
Study findings illustrate the need for better communication between health care providers and patients experiencing concerns during the pandemic.
- Global Stomach Cancer Treatment Market – 2019-2026on February 26, 2021 at 9:46 am
This report studies about the stomach cancer which is a disease and in which malignant (cancer) cells forms in the lining ...
- Considering the potential for gene-based therapy in prostate canceron February 26, 2021 at 4:03 am
Prostate cancer lends itself to gene therapies, and multiple aspects of prostate cancer care make gene therapy an appealing treatment option for this common malignancy. Although laboratory and ...
- Could Fruit Flies Help Match Patients With Cancer Treatments?on February 25, 2021 at 11:00 pm
A British company is seeding genetically modified flies with human tumors, giving patients their own personal drug trials.
- Liquid biopsy could guide therapy for colorectal canceron February 25, 2021 at 11:54 am
Liquid biopsies can gauge the effectiveness of therapy for colorectal cancer that has begun to spread beyond the original tumor, researchers report.
- Why Is Liver Cancer More Lethal for Black Patients?on February 25, 2021 at 9:26 am
Despite often being more advanced, liver cancer in Black people is slower to cause liver damage and scarring, and current guidelines call for liver cancer screening only after such scarring (cirrhosis ...
via Bing News
The Latest on: Multiple myeloma
- FDA approves Oncopeptides' PEPAXTO® ( melphalan flufenamide) for patients with relapsed or refractory multiple myelomaon February 26, 2021 at 3:34 pm
Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO), a global biotech company focused on the development of therapies for difficult-to-treat hematological diseases, today announced that the U.S. Food and ...
- Bluebird bio up after peer-reviewed publication of ide-cel data in multiple myelomaon February 25, 2021 at 7:29 am
The New England Journal of Medicine has published the Phase 2 study results for CAR T cell immunotherapy, idecabtagene vicleucel (ide-cel; bb2121) developed by ...
- International Myeloma Foundation (IMF) Launches 31 Days of Resilience Campaign for Myeloma Action Month in March 2021on February 25, 2021 at 6:14 am
Spearheaded by the International Myeloma Foundation, Myeloma Action Month takes place every March to encourage individuals and groups to take actions that positively impact the myeloma community. This ...
- CAR T-cell therapy generates lasting remissions in patients with multiple myelomaon February 24, 2021 at 11:55 pm
In a major advance in the treatment of multiple myeloma, a CAR T-cell therapy has generated deep, sustained remissions in patients who had relapsed from several previous therapies, an international ...
- Multiple Myeloma Therapy Market By Industry Research, Supply, Size, Share and Prospects 2020-2027 By Ameco Researchon February 24, 2021 at 9:30 pm
Multiple Myeloma Therapy market to help players in achieving a strong market position. Buyers of the report can access verified and reliable market forecasts, including those for the overall size The ...
- CAR T-cell therapy produces deep, sustained remissions in patients with relapsed myelomaon February 24, 2021 at 4:14 pm
In a major advance in the treatment of multiple myeloma, a CAR T-cell therapy has generated deep, sustained remissions in patients who had relapsed from several previous therapies, an international ...
- Suppression of steroid 5α-reductase type I promotes cellular apoptosis and autophagy via PI3K/Akt/mTOR pathway in multiple myelomaon February 24, 2021 at 9:32 am
Steroid 5α-reductase type I (SRD5A1) is a validated oncogene in many sex hormone-related cancers, but its role in multiple myeloma (MM) remains unknown. Based on gene expression profiling (GEP) of ...
- Enriched CAR-T Shows Durable Responses in Multiple Myelomaon February 22, 2021 at 11:17 am
T-cell therapy called bb21217 improved responses and prolonged duration of response compared with non-enriched CAR T cells in patients with relapsed/refractory multiple myeloma, according to results ...
- Identification of resistance pathways and therapeutic targets in relapsed multiple myeloma patients through single-cell sequencingon February 22, 2021 at 9:25 am
Integration of longitudinal single-cell analysis of relapsed and refractory multiple myeloma patients in a prospective clinical trial uncovers new pathways of drug resistance and identifies potential ...
- Multiple Myeloma Drugs Market Size 2020 by Capacity, Production, Revenue, Price, Cost, Gross Margin Analysis and Forecast to 2024on February 19, 2021 at 12:35 am
Feb (The Expresswire) -- "Final Report will add the analysis of the impact of COVID-19 on this industry." Multiple myeloma is a cancer that forms ...
via Bing News
